Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration

Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration

Tryfon Rotsos, Praveen J Patel, Fred K Chen, Adnan TufailMedical Retina Service, Moorfields Eye Hospital, London, UKPurpose: To describe the visual acuity and safety outcomes for the first 50 patients with neovascular age-related macular degeneration (nAMD) treated with ranibizumab at Moorfields Eye...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Tryfon Rotsos, Praveen J Patel, Fred K Chen, et al
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2010
Materias:
Ophthalmology
RE1-994
Acceso en línea:https://doaj.org/article/dd4fa73667e04d26ba0577c29b9925d7
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:dd4fa73667e04d26ba0577c29b9925d7
record_format dspace
spelling oai:doaj.org-article:dd4fa73667e04d26ba0577c29b9925d72021-12-02T09:06:34ZInitial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration1177-54671177-5483https://doaj.org/article/dd4fa73667e04d26ba0577c29b9925d72010-11-01T00:00:00Zhttp://www.dovepress.com/initial-clinical-experience-of-ranibizumab-therapy-for-neovascular-age-a5626https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Tryfon Rotsos, Praveen J Patel, Fred K Chen, Adnan TufailMedical Retina Service, Moorfields Eye Hospital, London, UKPurpose: To describe the visual acuity and safety outcomes for the first 50 patients with neovascular age-related macular degeneration (nAMD) treated with ranibizumab at Moorfields Eye Hospital.Methods: A retrospective analysis of case notes from the first 50 consecutive patients with Primary Care Trust funding for ranibizumab therapy for nAMD. Visual acuity outcomes and adverse events were noted, as were service delivery-related indicators.Results: The mean (±standard deviation) age of the 50 patients was 81 ± 17 years. The mean follow-up of patients was 13.6 ± 2 (range 7.7–18) months. The mean change in visual acuity ± standard error was +4.6 ± 2.2 letters at the end of follow-up, with 26% gaining 15 letters or more. The mean (median) number of injections was 4.7 (4.5) per 12-month period. The mean (median) delay in Primary Care Trust funding approval was 35 days (32 days) prior to the final appraisal document from the National Institute of Health and Clinical Excellence.Conclusions: The real-world outcomes of ranibizumab therapy in this initial cohort of patients with nAMD are comparable with those reported in the pivotal, randomized, controlled trials using fewer injections and a prn strategy of retreatment to achieve the gain in visual acuity.Keywords: macular degeneration, retina, ranibizumab Tryfon RotsosPraveen J PatelFred K Chenet alDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2010, Iss default, Pp 1271-1275 (2010)
institution DOAJ
collection DOAJ
language EN
topic Ophthalmology
RE1-994
spellingShingle Ophthalmology
RE1-994
Tryfon Rotsos
Praveen J Patel
Fred K Chen
et al
Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration
description Tryfon Rotsos, Praveen J Patel, Fred K Chen, Adnan TufailMedical Retina Service, Moorfields Eye Hospital, London, UKPurpose: To describe the visual acuity and safety outcomes for the first 50 patients with neovascular age-related macular degeneration (nAMD) treated with ranibizumab at Moorfields Eye Hospital.Methods: A retrospective analysis of case notes from the first 50 consecutive patients with Primary Care Trust funding for ranibizumab therapy for nAMD. Visual acuity outcomes and adverse events were noted, as were service delivery-related indicators.Results: The mean (±standard deviation) age of the 50 patients was 81 ± 17 years. The mean follow-up of patients was 13.6 ± 2 (range 7.7–18) months. The mean change in visual acuity ± standard error was +4.6 ± 2.2 letters at the end of follow-up, with 26% gaining 15 letters or more. The mean (median) number of injections was 4.7 (4.5) per 12-month period. The mean (median) delay in Primary Care Trust funding approval was 35 days (32 days) prior to the final appraisal document from the National Institute of Health and Clinical Excellence.Conclusions: The real-world outcomes of ranibizumab therapy in this initial cohort of patients with nAMD are comparable with those reported in the pivotal, randomized, controlled trials using fewer injections and a prn strategy of retreatment to achieve the gain in visual acuity.Keywords: macular degeneration, retina, ranibizumab
format article
author Tryfon Rotsos
Praveen J Patel
Fred K Chen
et al
author_facet Tryfon Rotsos
Praveen J Patel
Fred K Chen
et al
author_sort Tryfon Rotsos
title Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration
title_short Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration
title_full Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration
title_fullStr Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration
title_full_unstemmed Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration
title_sort initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration
publisher Dove Medical Press
publishDate 2010
url https://doaj.org/article/dd4fa73667e04d26ba0577c29b9925d7
work_keys_str_mv AT tryfonrotsos initialclinicalexperienceofranibizumabtherapyforneovascularagerelatedmaculardegeneration
AT praveenjpatel initialclinicalexperienceofranibizumabtherapyforneovascularagerelatedmaculardegeneration
AT fredkchen initialclinicalexperienceofranibizumabtherapyforneovascularagerelatedmaculardegeneration
AT etal initialclinicalexperienceofranibizumabtherapyforneovascularagerelatedmaculardegeneration
_version_ 1718398275031138304

Ejemplares similares